Aerie initiates second phase 3 registration trial of Roclatan

Aerie Pharmaceuticals began dosing patients enrolled in the second phase 3 registration trial of Roclatan, according to a company press release. Roclatan (0.02% netarsudil, 0.005% latanoprost ophthalmic solution) is a once-daily eye drop being tested for its ability to lower IOP in patients with glaucoma or ocular hypertension.